×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SYRE – spyre therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SYRE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
10:00 am
syre
Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities Investigation
Low
Report
Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities Investigation
11/20
10:00 am
syre
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
11/20
10:00 am
syre
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out
Low
Report
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out
11/19
03:15 pm
syre
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
11/18
09:18 pm
syre
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
Medium
Report
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
11/18
04:14 pm
syre
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
Medium
Report
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
11/13
08:05 am
syre
Spyre Therapeutics, Inc. (NASDAQ: SYRE) had its price target raised by analysts at Robert W. Baird from $50.00 to $65.00. They now have an "outperform" rating on the stock.
Medium
Report
Spyre Therapeutics, Inc. (NASDAQ: SYRE) had its price target raised by analysts at Robert W. Baird from $50.00 to $65.00. They now have an "outperform" rating on the stock.
11/12
07:30 am
syre
Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-a4ß7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential f
High
Report
Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-a4ß7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential f
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/19
05:15 pm
syre
Form 8-K Spyre Therapeutics, Inc. For: Nov 18
Low
Report
Form 8-K Spyre Therapeutics, Inc. For: Nov 18
11/19
04:39 pm
syre
Form 424B5 Spyre Therapeutics, Inc.
Low
Report
Form 424B5 Spyre Therapeutics, Inc.
11/18
05:10 pm
syre
Form 424B5 Spyre Therapeutics, Inc.
Medium
Report
Form 424B5 Spyre Therapeutics, Inc.
11/18
04:10 pm
syre
Form 10-Q/A Spyre Therapeutics, Inc. For: Sep 30
Medium
Report
Form 10-Q/A Spyre Therapeutics, Inc. For: Sep 30
11/18
04:07 pm
syre
Form 10-Q/A Spyre Therapeutics, Inc. For: Jun 30
Medium
Report
Form 10-Q/A Spyre Therapeutics, Inc. For: Jun 30
11/18
04:06 pm
syre
Form 10-Q/A Spyre Therapeutics, Inc. For: Mar 31
Medium
Report
Form 10-Q/A Spyre Therapeutics, Inc. For: Mar 31
11/18
04:04 pm
syre
Form 10-K/A Spyre Therapeutics, Inc. For: Dec 31
Medium
Report
Form 10-K/A Spyre Therapeutics, Inc. For: Dec 31
11/18
04:02 pm
syre
Form 8-K Spyre Therapeutics, Inc. For: Nov 18
Medium
Report
Form 8-K Spyre Therapeutics, Inc. For: Nov 18
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: